Is AI Slashing Pharma Jobs? Why the Laboratory Might Be Safer Than the Office

While a wave of AI-fueled layoffs ripples through the tech world, the pharmaceutical and biotech industries are currently holding a different line. From Super Bowl ads to corporate boardrooms, artificial intelligence was the defining trend of 2025, sparking a mix of wonder and “handwringing” over everything from environmental costs to the future of the human workforce.

Across the broader corporate landscape, the shift has been jarring. Giants like Amazon have cut tens of thousands of roles, with leadership openly stating that generative AI and digital agents will fundamentally reduce the number of people needed for traditional tasks. Yet, in the high-stakes world of medicine, the story isn’t about replacement—it’s about evolution.

Reshaping, Not Replacing

Industry experts suggest that biopharma may be spared from the “one-for-one” job replacement seen in retail or tech. Jae Yoo, executive director of the recruitment firm EPM Scientific, describes the current shift as a “rehousing and reshaping” of roles. Rather than deleting positions, companies are moving talent into new areas where human intuition meets machine speed.

This sentiment is shared at the highest levels of the “C-suite.” Leaders at Pfizer, for instance, have framed AI as a tool that elevates existing roles. By automating the “routine and repetitive,” the industry is placing a higher premium on essential human traits: curiosity, creativity, and critical thinking.

The Rise of the AI Factory

While biotech has seen its share of volatility recently, those losses haven’t been directly linked to AI. In fact, some of the biggest names in the game are hiring specifically because of it. Eli Lilly recently partnered with NVIDIA to build an “AI factory for drug discovery” in San Francisco, a move designed to create entirely new scientific and technical roles rather than eliminate them.

This surge in demand is reflected in recent surveys, where more than half of biotech executives identified AI expertise as a top-three hiring priority for the coming years. Interestingly, companies are moving away from outsourcing these technical tasks to third-party vendors. Instead, they are building massive in-house analytics teams, preferring to have their own specialists overseeing the data that leads to the next breakthrough.

The New Hybrid Professional

The AI revolution is also blurring the lines between traditional departments. We are seeing the emergence of “hybrid” roles that require a cross-functional skillset—merging areas like commercial analytics with market access. Employers are no longer just looking for a technical expert in one narrow field; they want professionals who can navigate the entire lifecycle of a drug.

Drug discovery remains the most fertile ground for this growth. AI allows researchers to identify potential therapies at a fraction of the traditional cost and time, creating an urgent need for machine learning engineers who understand the nuances of biology. Similarly, roles that impact “time-to-market”—such as commercial data analysis and regulatory success—remain in high demand because they directly influence a company’s ability to help patients.

A Mission-Driven Buffer

Perhaps the greatest protection for pharma workers lies in the industry’s core mission. While tech companies often prioritize the immediate bottom line, pharmaceutical firms are tethered to the long-term, complex process of developing life-saving therapies. In this environment, the human element isn’t just a cost—it’s a necessity for navigating the ethical and regulatory hurdles of patient care. For now, while AI handles the data, the humans are still running the lab.

Source: PharmaVoice | February 18 2026